Tiburio is dedicated to developing transformative treatments for patients with rare endocrine diseases.
At Tiburio, we are building an exceptional company dedicated to the development of novel treatments for rare endocrine diseases where significant need exists.
Tiburio is developing TBR-760, a dopamine-somatostatin chimeric compound, for the treatment of non-functioning pituitary adenomas (NFPAs). Tiburio’s development-stage pipeline includes TBR-065, another dopamine somatostatin chimeric compound for other rare endocrine diseases.
Patients and Clinical Community
Development of meaning and sustainable products requires a deep understanding of patients’ and physicians’ perspectives on treatment needs. To drive our efforts, we build authentic and long-standing relationships with the patient and clinical communities we serve.
Work Environment and Employees
Successful drug development requires collaboration and excellent execution in thriving work environments. We will be purposeful about integrity and respect in our work with a specific focus on making reasoned decisions and working efficiently with high accountability.
Drug development requires thoughtful investment and may not take a linear path. We will transparently inform our investors on the opportunities and risks associated with our efforts while always being mindful of how we allocate their capital.
The company was launched out of orphan drug accelerator Cydan, with financing from life science investors NEA, Lundbeckfonden Ventures, Longitude Capital and Alexandria Venture Investments.